Table 4.
Summary of previously reported SARS-CoV-2 antibody response rate among patients with solid tumors receiving various treatments
| Publication, Therapy subgroups | Positive/all (n) | Serologic RR (%) Rate (%) |
|---|---|---|
| Studies including solid tumor patients only | ||
| Massarweh et al.15 | ||
| All | 92/102 | 90 |
| All chemo combinations | 55/64 | 85.8 |
| All immuno combinations | 36/41 | 87.8 |
| IC only (22) or +biologic (5) | 26/27 | 96.2 |
| Immuno + chemo | 10/14 | 71.4 |
| Goshen-Lago et al.16 | ||
| All | 187/218 | 85.8 |
| All chemo combinations | 102/125 | 81.6 |
| Biologic | 70/77 | 90.9 |
| All immuno combinations | 8/79 | 89.9 |
| Barriere et al.14 | ||
| All | 42 | 95.2 |
| Grinshpun, Rottenberg et al., this study | ||
| All | 150/172 | 87.2 |
| All chemo combinations | 63/80 | 77.5 |
| All immuno | 4/46 | 91.3 |
| Immuno only | 32/34 | 94.1 |
| Immuno + chemo | 10/12 | 83.3 |
| Studies that included hematologic patients (solid tumor patients are extracted, but specific treatment groups include hematologic patients) | ||
| Thakkar et al.12 | ||
| All solid tumor patients | 136 | 98 |
| Chemotherapy | 112 | 93 |
| Immunotherapy | 31 | 97 |
| Other | 47 | 100 |
| Addeo et al.13 | ||
| All solid tumor patients | 101 | 98 |
| Cytotoxic | 30 | 93 |
| Immunotherapy | 14 | 92.8 |
| Other | 63 | 98.4 |
| Iacono et al.17 (>age 80) | ||
| All solid tumor patients | 26 | 96 |
Chemo, chemotherapy; IC, immunotherapy; immune, immunotherapy.